|

LP-168 Clinical Trials

2 actively recruiting trials across 2 locations

Durham, North Carolina1 trial

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Duke Univerisity

Phase 1

Cincinnati, Ohio1 trial

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

University of Cincinnati Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.